stockrow
Friday 6 November 2026
Export BTAIQ’s income statement to Excel — free account
BioXcel Therapeutics, Inc.
BTAIQ Healthcare Drug Manufacturers Specialty & Generic
BioXcel Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $642,000.00, down 71.7% from fiscal 2024.
- Revenue
- +51.7%
- EPS
- +80.0%
- Free cash flow
- +51.5%
- Total debt
- −3.90%
Quarter to June 2026, against a year earlier
0.01
0.00
0.00%
Follow BTAIQ
Alert me
BioXcel Therapeutics, Inc. (BTAIQ) P/E ratio
BioXcel Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 12 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SBFM Sunshine Biopharma, Inc. compare | n/m |
| SXTC China SXT Pharmaceuticals, Inc. compare | n/m |
| APUS Apimeds Pharmaceuticals US, Inc. compare | n/m |
| YCBD cbdMD, Inc. compare | n/m |
| PRFX PainReform Ltd. compare | n/m |
| RDHL Redhill Biopharma Ltd. compare | n/m |
| IMCC IM Cannabis Corp. compare | n/m |
| BTAIQ BioXcel Therapeutics, Inc. | n/m |
| AKAN Akanda Corp. compare | — |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)